Education
About Us
Working with TipRanks
Follow Us
Elekta AB (EKTAY)
OTHER OTC:EKTAY
EKTAY Stock Chart & Stats
$6.37
-$0.10(-1.78%)
At close: 4:00 PM EST
$6.37
-$0.10(-1.78%)
Day’s Range― - ―
52-Week Range$4.42 - $6.88
Previous CloseN/A
Volume122.00
Average Volume (3M)73.00
Market Cap
$2.37B
Enterprise Value$25.35B
Total Cash (Recent Filing)$2.58B
Total Debt (Recent Filing)$7.60B
Price to Earnings (P/E)82.2
Beta1.29
Next Earnings
Mar 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.21%
Share Statistics
EPS (TTM)0.06
Shares Outstanding368,588,000
10 Day Avg. Volume0
30 Day Avg. Volume73
Financial Highlights & Ratios
PEG Ratio-0.96
Price to Book (P/B)2.12
Price to Sales (P/S)1.04
P/FCF Ratio17.69
Enterprise Value/Market Cap10.69
Enterprise Value/Revenue1.44
Enterprise Value/Gross Profit3.80
Enterprise Value/Ebitda11.71
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Free Cash Flow StrengthSustained 24.5% FCF growth improves Elekta's internal funding capacity, lowering reliance on external financing. Durable cash generation supports R&D, service expansion, debt paydown and resilience through healthcare capital cycles, enabling strategic execution over coming quarters.
Balanced LeverageA debt-to-equity ratio near 0.90 and a healthy equity base gives Elekta financial flexibility to fund product development and weather project timing variability. Prudent leverage enhances balance-sheet stability and preserves capacity for targeted investments across multi-quarter procurement cycles.
Recurring Service Revenue Growth7% service growth signals expansion of recurring revenue from maintenance, upgrades and software. A larger installed-base services business reduces cyclicality tied to capital equipment sales, boosts lifetime customer value and provides a steadier revenue base for reinvestment.
Bears Say
Weakness In U.S. MarketAn 8% decline in the Americas, driven by U.S. weakness, reflects structural commercial execution challenges in a key market. Prolonged underperformance there can erode share in a high-margin region, require sustained remedial investment, and limit medium-term revenue recovery.
Low Return On EquityA modest ROE (~3.15%) and low net margins indicate limited returns on shareholder capital. Persistently low profitability constrains organic funding for growth, raises pressure on management to improve margins or alter product mix, and can limit long-term shareholder value creation.
Order Volatility / Backlog RiskA SEK 2.2bn backlog cancellation following a stricter order review highlights structural sensitivity to tender terms and project criteria. Such order volatility reduces revenue visibility across quarters and increases execution risk in large, timetable-dependent capital-equipment sales.
Elekta AB News
EKTAY FAQ
What was Elekta AB’s price range in the past 12 months?
Elekta AB lowest stock price was $4.42 and its highest was $6.88 in the past 12 months.
What is Elekta AB’s market cap?
Elekta AB’s market cap is $2.37B.
When is Elekta AB’s upcoming earnings report date?
Elekta AB’s upcoming earnings report date is Mar 05, 2026 which is in 16 days.
How were Elekta AB’s earnings last quarter?
Elekta AB released its earnings results on Nov 26, 2025. The company reported $0.063 earnings per share for the quarter, beating the consensus estimate of N/A by $0.063.
Is Elekta AB overvalued?
According to Wall Street analysts Elekta AB’s price is currently Overvalued.
Does Elekta AB pay dividends?
Elekta AB pays a Semiannually dividend of $0.064 which represents an annual dividend yield of 0.21%. See more information on Elekta AB dividends here
What is Elekta AB’s EPS estimate?
Elekta AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elekta AB have?
Elekta AB has 368,588,000 shares outstanding.
What happened to Elekta AB’s price movement after its last earnings report?
Elekta AB reported an EPS of $0.063 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 24.11%.
Which hedge fund is a major shareholder of Elekta AB?
Currently, no hedge funds are holding shares in EKTAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elekta AB Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.41%
12-Months-Change
Fundamentals
Return on Equity
2.57%
Trailing 12-Months
Asset Growth
1.90%
Trailing 12-Months
Company Description
Elekta AB
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
EKTAY Company Deck
EKTAY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mix of positive developments and ongoing challenges. Elekta reported strong performance in Europe, growth in service business, and positive trends in China, alongside improved cash flow and debt reduction. However, challenges persist in the U.S. market, with order cancellations and gross margin recovery issues. The new operating model and cost reductions highlight a proactive approach to addressing these challenges.View all EKTAY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
<0.01% Other Institutional Investors
99.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---